colorectal cancer is still one of the main current problems in modern, interdisciplinary clinical oncology. Therefore, the columns of our journal will always be open to presentations of up-to-date therapies that can improve prognosis in this group of patients. One of the modern chemotherapeutics approved by the European Medicines Agency (EMA) for the treatment of patients with metastatic colorectal cancer is trifluridine/tipiracil. Clinical experiences with these new drug are the subject of a series of papers published in the latest issue of “OncoReview”. Outstanding oncologists practitioners present their experiences with an innovative approach to the fight against cancer, which allows to delay the progression of the disease instead of periodically repeating the previously used, ineffective chemotherapy regimens.
We do not forget, however, about cardio-oncology, which in the current issue is represented by case studies on indications for transcatheter aortic valve replacement (TAVR) and for prophylactic antithrombotic therapy in cancer patients.
prof. Eric E. Harrison, MD, Fellow of ACC, AHA, ASAI, ACP
Radosław Grabysa, MD, PhD, Associate Professor